NCT03260868 - Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 19, 2017

Primary Completion Date

November 22, 2018

Study Completion Date

November 22, 2018

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG

Insulin glargine, 300 units per milliliter (U/mL)

Self-administered subcutaneous injection using prefilled pen once daily for 24 weeks. Dose titration to achieve fasting self-monitoring of plasma glucose (SMPG) level between 80 and 130 milligram per deciliter (mg/dL).

DRUG

Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)

Subcutaneous injection.

Trial Locations (6)

26330

Investigational Site Number 8400003, Bridgeport

50265

Investigational Site Number 8400002, West Des Moines

77043

Investigational Site Number 8400004, Houston

L4M 7G1

Investigational Site Number 1240001, Barrie

L6M 1M1

Investigational Site Number 1240003, Oakville

L4J 8L7

Investigational Site Number 1240002, Thornhill